6 results about "Dna antibody" patented technology

The application relates to an ANA and dsDNA fluorescence image processing method, device and computer equipment. The method comprises the following steps: acquiring a fluorescence microscope shooting image; in response to a detection item selection operation on the fluorescence microscope shooting image, determining a detection item identifier associated with the fluorescence microscope shooting image; according to the detection item identifier associated with the fluorescence microscope shooting image, distributing the fluorescence microscope shooting image to a corresponding image detection pipeline, so that the image detection pipeline detects and processes the fluorescence microscope shooting image according to an image detection algorithm process matched with the detection item identifier, and obtains a structured detection result corresponding to the fluorescence microscope shooting image; and displaying the structured detection result corresponding to the fluorescence microscope shooting image. The method can improve the laboratory detection efficiency of an anti-nuclear antibody and an anti-double-stranded DNA antibody fluorescence image.

The present disclosure is directed to methods for treating a neuropsychiatric disorder associated with expression of autoantibodies to ionotropic glutamate receptor, NMD A 2A (GiuN2A), expression of anti-double-stranded (ds) DNA antibodies that cross react with one or more subunits of the NMD A receptor, or a mutation in the ionotropic glutamate receptor NMD A type subunit 2A (GRIN2A) gene. The methods involve administering a memantine, or a pharmaceutically acceptable salt thereof, to a subject suffering from a neuropsychiatric disorder associated with expression of GluN2A or a mutation in the GRIN2A gene.

Compositions for improved gene editing and methods of use thereof are disclosed. In a preferred method, gene editing involves use of a cell-penetrating anti-DNA antibody, such as 3E10, as a potentiating agent to enhance gene editing by nucleases and triplex forming oligonucleotides. Genomic modification occurs at a higher frequency when cells are contacted with the potentiating agent and nuclease or triplex forming oligonucleotide, as compared to the absence of the potentiating agent. The methods are suitable for both ex vivo and in vivo approaches to gene editing and are useful for treating a subject with a genetic disease or disorder. Nanoparticle compositions for intracellular delivery of the gene editing compositions are provided and are particularly advantageous for use with in vivo applications.

Disclosed herein are compositions for generating a synthetic antibody or synthetic multivalent antibody in a subject. Also disclosed are methods for generating a synthetic antibody or synthetic multivalent antibody in a subject by administering a composition including one or more recombinant nucleic acid sequence that encodes a synthetic antibody or synthetic multivalent antibody to the subject. The disclosure also provides a compositions and methods of preventing and / or treating a Neisseria gonorrhoeae infection in a subject using said synthetic antibody or synthetic multivalent antibody.

Methods of detecting biomarkers in a blood sample obtained from a human subject include detecting an erythrocyte-bound C4d (EC4d) marker, a B-lymphocyte-bound C4d (BC4d) marker, and an anti-nuclear antibody (ANA) in the blood sample; and detecting a level of double-stranded DNA antibody in the blood sample, wherein the human subject is negative for systemic lupus erythematosus based on the level of double-stranded DNA antibody. The methods optionally further include determining a systemic lupus erythematosus risk score by: (a) adjusting the level of EC4d marker by a weighting coefficient to produce a weighted score for EC4d marker; (b) adjusting the level of BC4d marker by a weighting coefficient to produce a weighted score for BC4d marker; (c) adjusting the level of ANA by a weighting coefficient to produce a weighted score for ANA; and (d) combining the weighted score for EC4d marker, the weighted score for BC4d marker, and the weighted score for ANA to generate the systemic lupus erythematosus risk score; wherein the systemic lupus erythematosus risk score does not include a score for double-stranded DNA antibody.

Disclosed herein are compositions for generating a synthetic antibody or synthetic multivalent antibody in a subject. Also disclosed are methods for generating a synthetic antibody or synthetic multivalent antibody in a subject by administering a composition including a recombinant nucleic acid sequence that encodes an antibody, a synthetic antibody, or a synthetic multivalent antibody to a subject. The disclosure also provides compositions and methods of preventing and / or treating a bacterial infection in a subject using said antibody, synthetic antibody, or synthetic multivalent antibody.